Skip to content
Pharma Observatory a Scientist.com platform

Organization (Other)

Peking University Cancer Hospital & Institute

ClinicalTrials.gov lists Peking University Cancer Hospital & Institute as lead sponsor of 265 trials. It has 219 active development programs and 38 approved assets.

Other
Email me this page as a PDF

Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

68 0 2006 2027

Trials started per year with this organization as sponsor or collaborator, 1990 onward. The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.

2026 is partial: 56 registered with a 2026 start date. The hollow diamonds on the dashed line are a forecast of the full-year count, planned starts included: about 68 in 2026 and about 59 in 2027, the average of the 24 months through September, counted as registered and carried forward. The columns, the lighter one included, count trials registered so far with a start date in the year, planned starts included; the forecast looks ahead to the count for the whole year, so it is not the same measure. This method has not been backtested on organizations. In backtests on conditions with as many trial starts a year as this organization (20 to 100), forecasts made part-way through the year were typically off by about 18 percent and ran about 14 percent low against the count later registered; forecasts made before the year began were off by about 26 percent and ran about 20 percent low against the count later registered. These figures rest on a few years of history (target years from 2018 to 2025, varying by figure), place each condition as it is mapped today rather than as it was then, and score against a count for the newest year that was still being revised. Only condition series were scored. 1 trial is registered to start in 2027 or later.

This page covers Peking University Cancer Hospital & Institute: 265 lead-sponsored trials and 0 legal-entity registrations.

Get the Peking University Cancer Hospital & Institute report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Disease areas (99)

Shown in this order: most trials first.

Disease areas
Disease area Trials
Colorectal Neoplasms 64
Lung Neoplasms 51
Head and Neck Neoplasms 41
Breast Neoplasms 38
Esophageal Neoplasms 33

Trials by start year as sponsor or collaborator (19)

Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year. 1 trial is registered to start in 2027 or later, and not listed here.

Show the table of trials by start year as sponsor or collaborator
Trials by start year as sponsor or collaborator
Year Trials started
2026 (partial year) 56
2025 55
2024 44
2023 41
2022 26
2021 37
2020 34
2019 31
2018 23
2017 28

Prediction, not a registry value: median of 36 months from start to primary completion across 50 trials still running at the 2026-10-09 snapshot; registered median of 36 months across 38 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.

Active development programs (219)

Shown in this order: max phase, then active trials.

Active development programs
Drug Disease area Max phase Trials
SUNITINIB Kidney Neoplasms Phase 3 2
SUNITINIB Carcinoma, Renal Cell Phase 3 2
Camrelizumab +Immunotherapy Colorectal Neoplasms Phase 3 1
Vorolanib Tablets+Everolimus Kidney Neoplasms Phase 3 1
Vorolanib Tablets+Everolimus Carcinoma, Renal Cell Phase 3 1

Approved assets (38)

Shown in this order: max phase first.

Approved assets
Drug Trials
Traditional Chinese medicine (TCM) hand and foot baths 1
Iparomlimab and Tuvonralimab (QL1706)Injection 1
Dose Escalation 1
OH2 Injection 1
Mecobalamin 1

Sponsor delivery record (1)

Enrollment hit target: the share of this sponsor's lead-sponsored trials whose actual enrollment reached the planned enrollment. On time: the share whose actual primary completion date was no later than the planned date. Each share counts only trials where we observed an estimated figure before the actual one, and n is that number of trials. Below 5 trials the count is shown as a fraction, not a percentage.

Sponsor delivery record
Enrollment Timeline
57% hit target (n=23) 41% on time (n=22)

Journals published in (237)

Shown in this order: most published in first.

Journals published in
Journal Publications
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 40
The Lancet. Oncology 19
The New England journal of medicine 18
Clinical cancer research : an official journal of the American Association for Cancer Research 14
European journal of cancer (Oxford, England : 1990) 14

Organization relationships (94)

Shown in this order: most evidence first.

Organization relationships
Related organization Relationship Evidence
Cancer Institute and Hospital, Chinese Academy of Medical Sciences Co sponsors trial with 14
West China Hospital Co sponsors trial with 11
Shanghai Zhongshan Hospital Co sponsors trial with 8
Jiangsu Cancer Institute & Hospital Co sponsors trial with 8
Shandong Cancer Hospital and Institute Co sponsors trial with 7

Latest dated events (459)

Shown in this order: newest first.

Latest dated events
Date Event Source
2027-01-01 Trial started Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI))
2026-10-22 Trial started Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI))
2026-10 Trial started Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI))
2026-10-01 Trial started Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI))
2026-09-30 Trial started Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI))

Biomarker capability evidence (1,232)

Shown in this order: tier desc, then gene symbol.

Biomarker capability evidence
Gene Role Evidence
ACE2 Trial sponsor Named in trial inclusion criteria
ACE2 Trial sponsor Named in trial inclusion criteria
AFP Trial sponsor Named in trial inclusion criteria
ALB Trial sponsor Named in trial inclusion criteria
ALB Trial sponsor Named in trial inclusion criteria

Not on this page

Checked, with nothing recorded for this organization: companies grouped under this page, related companies not grouped here, us granted patents, sec-reported annual financials, financing and grant events, fda warning letters, fda untitled letters, fda inspection record, fda recalls, fda import refusals, manufacturing and distribution sites, climate targets, as filed, workforce and board diversity, as filed, clia clinical laboratory certificates, and biomarkers this organization publishes on.